Immunex seeking court order to require FDA review of paclitaxel ANDA.
Executive Summary
IMMUNEX GENERIC PACLITAXEL ANDA: COURT ORDER SOUGHT TO COMPEL FDA REVIEW of Immunex' application for a generic version of Bristol-Myers Squibb's anticancer agent Taxol prior to the expiration of Bristol's five-year Waxman/Hatch exclusivity on Dec. 29. In a lawsuit filed July 25 in Washington, D.C. federal court, Immunex is seeking a permanent injunction "ordering FDA to accept for review Immunex' ANDA" for paclitaxel under the Paragraph IV certification process established by the 1984 Waxman/Hatch Act. Immunex is being represented by Hyman, Phelps & McNamara (Washington, D.C.).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth